A guide to immunotherapy for COVID-19
Fulltext:
248703.pdf
Embargo:
until further notice
Size:
2.060Mb
Format:
PDF
Description:
Publisher’s version
Publication year
2022Source
Nature Medicine, 28, 1, (2022), pp. 39-50ISSN
Publication type
Article / Letter to editor
Display more detailsDisplay less details
Organization
Internal Medicine
Intensive Care
Journal title
Nature Medicine
Volume
vol. 28
Issue
iss. 1
Page start
p. 39
Page end
p. 50
Subject
Radboudumc 4: lnfectious Diseases and Global Health RIHS: Radboud Institute for Health Sciences; Radboudumc 4: lnfectious Diseases and Global Health RIMLS: Radboud Institute for Molecular Life Sciences; Intensive Care - Radboud University Medical Center; Internal Medicine - Radboud University Medical CenterAbstract
Immune dysregulation is an important component of the pathophysiology of COVID-19. A large body of literature has reported the effect of immune-based therapies in patients with COVID-19, with some remarkable successes such as the use of steroids or anti-cytokine therapies. However, challenges in clinical decision-making arise from the complexity of the disease phenotypes and patient heterogeneity, as well as the variable quality of evidence from immunotherapy studies. This Review aims to support clinical decision-making by providing an overview of the evidence generated by major clinical trials of host-directed therapy. We discuss patient stratification and propose an algorithm to guide the use of immunotherapy strategies in the clinic. This will not only help guide treatment decisions, but may also help to design future trials that investigate immunotherapy in other severe infections.
This item appears in the following Collection(s)
- Academic publications [245284]
- Electronic publications [132642]
- Faculty of Medical Sciences [93207]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.